Find the right fit for you - faster
Get tailored insights about working at Aegerion in one quick step.
Aegerion Snapshot
Bad cholesterol, beware! Aegerion Pharmaceuticals is hot on your trail. The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Cutting LDL levels may add years to patients' lives and reduce the risk of cardiovascular events. Aegerion's lead development candidates are protein inhibitors that aim to block cholesterol production in the liver and intestine. The company filed to go public (for the second time) in 2010. It began trading late in the year after raising about $42 million through its IPO.
